Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)

Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).

The analyst commented, "NRIX reported 2Q24 earnings and provided a pipeline update. The release reiterated much of which we recently described in detail following our recent investor meetings with management (see note here). Most importantly, following NX-5948's recent update at EHA, additional data continue to be expected in 2H24 that are expected to include updates from both the CLL and NHL cohorts. Ahead of this, NRIX expects to define doses for dose expansion in CLL (200 mg + a higher dose). We continue to see NX-5948 as a potential best- in-class BTK degrader in CLL and as a program that will provide significant validation for NRIX's targeted protein degrader platform. We remain at Overweight with $35 PT."

For an analyst ratings summary and ratings history on Nurix click here. For more ratings news on Nurix click here.

Shares of Nurix closed at $22.03 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Precipio seeks shareholder votes to meet quorum for annual meeting
• SpaceX (SPCX) reaches new intraday/all-time highs